Antiviral therapy increases the risk of bacterial infections in HCV-infected cirrhotic patients awaiting liver transplantation: A retrospective study

Journal of Hepatology

Volumn 50, Issue 4, 2009, Pages 719-728

  Carrión, Jose A ^a   Martínez Bauer, Eva ^a   Crespo, Gonzalo ^a   Ramírez, Santseharay ^a   Pérez del Pulgar, Sofia ^a   García Valdecasas, Juan Carlos ^b   Navasa, Miquel ^a   Forns, Xavier ^a  

^a HOSPITAL CLÍNIC   (Spain)

^b INSTITUT D INVESTIGACIONS BIOMÈDIQUES AUGUST PI I SUNYER IDIBAPS   (Spain)

Author keywords

Cirrhosis; Interferon; Norfloxacin prophylaxis; Spontaneous bacterial peritonitis; Virological response

Indexed keywords

CEFOTAXIME; CEFTRIAXONE; HEMOGLOBIN; NORFLOXACIN; NOVEL ERYTHROPOIESIS STIMULATING PROTEIN; PEGINTERFERON ALPHA2A; RECOMBINANT GRANULOCYTE COLONY STIMULATING FACTOR; RIBAVIRIN; VIRUS RNA;

ADULT; AGED; ALPHA HEMOLYTIC STREPTOCOCCUS; ANEMIA; ANTIBIOTIC PROPHYLAXIS; ANTIVIRAL THERAPY; ARTICLE; ASCITES; ASPERGILLOSIS; ASPERGILLUS; BACTEREMIA; BACTERIAL INFECTION; BACTERIAL PERITONITIS; BLOOD TRANSFUSION; CASE CONTROL STUDY; CATHETER INFECTION; CAUSE OF DEATH; CELLULITIS; CONTROLLED STUDY; DECOMPENSATED LIVER CIRRHOSIS; DRUG DOSE INCREASE; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG FATALITY; DRUG SAFETY; ESCHERICHIA COLI; FEMALE; GENOTYPE; GRAM NEGATIVE INFECTION; GRAM POSITIVE INFECTION; HEMOGLOBIN BLOOD LEVEL; HEPATIC ENCEPHALOPATHY; HEPATITIS C; HEPATITIS C VIRUS; HOSPITAL ADMISSION; HUMAN; INCIDENCE; INFECTION PREVENTION; INFECTION RISK; KLEBSIELLA PNEUMONIAE; KLEBSIELLA PNEUMONIAE INFECTION; LIVER CIRRHOSIS; LIVER FAILURE; LIVER GRAFT REJECTION; LIVER TRANSPLANTATION; MAJOR CLINICAL STUDY; MALE; NEUTROPENIA; NEUTROPHIL COUNT; PNEUMONIA; PRIMARY PREVENTION; PRIORITY JOURNAL; RETROSPECTIVE STUDY; RISK FACTOR; SECONDARY PREVENTION; SEPTIC SHOCK; STAPHYLOCOCCUS AUREUS; STAPHYLOCOCCUS EPIDERMIDIS; STAPHYLOCOCCUS INFECTION; STENOTROPHOMONAS MALTOPHILIA; STREPTOCOCCUS VIRIDANS INFECTION; THROMBOCYTE COUNT; THROMBOCYTOPENIA; URINARY TRACT INFECTION; VIRUS ATTENUATION;

ADULT; AGED; ANTIVIRAL AGENTS; BACTERIAL INFECTIONS; CARCINOMA, HEPATOCELLULAR; FEMALE; HEPATITIS C; HUMANS; INCIDENCE; INTERFERON ALFA-2A; LIVER TRANSPLANTATION; MALE; MIDDLE AGED; PERITONITIS; POLYETHYLENE GLYCOLS; POSTOPERATIVE COMPLICATIONS; RECURRENCE; RIBAVIRIN; SAFETY; TIME FACTORS; VIRAL LOAD; WAITING LISTS; YOUNG ADULT;

EID: 61749085030     PISSN: 01688278     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jhep.2008.11.015     Document Type: Article

References (28)

1. Garcia-Retortillo M., Forns X., Feliu A., Moitinho E., Costa J., Navasa M., et al. Hepatitis C virus kinetics during and immediately after liver transplantation. Hepatology 35 (2002) 680-687
2. Berenguer M., Ferrell L., Watson J., Prieto M., Kim M., Rayon M., et al. HCV-related fibrosis progression following liver transplantation: increase in recent years. J Hepatol 32 (2000) 673-684
3. Garcia-Retortillo M., Forns X., Llovet J.M., Navasa M., Feliu A., Massaguer A., et al. Hepatitis C recurrence is more severe after living donor compared to cadaveric liver transplantation. Hepatology 40 (2004) 699-707
4. Forman L.M., Lewis J.D., Berlin J.A., Feldman H.I., and Lucey M.R. The association between hepatitis C infection and survival after orthotopic liver transplantation. Gastroenterology 122 (2002) 889-896
5. Everson G.T. Treatment of patients with hepatitis C virus on the waiting list. Liver Transpl 9 (2003) S90-S94
6. Forns X., Garcia-Retortillo M., Serrano T., Feliu A., Suarez F., de la Mata M., et al. Antiviral therapy of patients with decompensated cirrhosis to prevent recurrence of hepatitis C after liver transplantation. J Hepatol 39 (2003) 389-396
7. Everson G.T., Trotter J., Forman L., Kugelmas M., Halprin A., Fey B., et al. Treatment of advanced hepatitis C with a low accelerating dosage regimen of antiviral therapy. Hepatology 42 (2005) 255-262
8. Nevens F., Goubau P., Van Eyken P., Desmyter J., Desmet V., and Fevery J. Treatment of decompensated viral hepatitis B-induced cirrhosis with low doses of interferon alpha. Liver 13 (1993) 15-19
9. Crippin J.S., McCashland T., Terrault N., Sheiner P., and Charlton M.R. A pilot study of the tolerability and efficacy of antiviral therapy in hepatitis C virus-infected patients awaiting liver transplantation. Liver Transpl 8 (2002) 350-355
10. Iacobellis A., Siciliano M., Perri F., Annicchiarico B.E., Leandro G., Caruso N., et al. Peginterferon alfa-2b and ribavirin in patients with hepatitis C virus and decompensated cirrhosis: a controlled study. J Hepatol 46 (2007) 206-212
11. Fernandez J., Navasa M., Planas R., Montoliu S., Monfort D., Soriano G., et al. Primary prophylaxis of spontaneous bacterial peritonitis delays hepatorenal syndrome and improves survival in cirrhosis. Gastroenterology 133 (2007) 818-824
12. Navasa M., and Forns X. Antiviral therapy in HCV decompensated cirrhosis: to treat or not to treat?. J Hepatol 46 (2007) 185-188
13. Fernandez J., Navasa M., Gomez J., Colmenero J., Vila J., Arroyo V., et al. Bacterial infections in cirrhosis: epidemiological changes with invasive procedures and norfloxacin prophylaxis. Hepatology 35 (2002) 140-148
14. Rimola A., Garcia-Tsao G., Navasa M., Piddock L.J., Planas R., Bernard B., et al. Diagnosis, treatment and prophylaxis of spontaneous bacterial peritonitis: a consensus document. International Ascites Club. J Hepatol 32 (2000) 142-153
15. Prieto M., Berenguer M., Rayon J.M., Cordoba J., Arguello L., Carrasco D., et al. High incidence of allograft cirrhosis in hepatitis C virus genotype 1b infection following transplantation: relationship with rejection episodes. Hepatology 29 (1999) 250-256
16. Berenguer M., Prieto M., Rayon J.M., Mora J., Pastor M., Ortiz V., et al. Natural history of clinically compensated hepatitis C virus-related graft cirrhosis after liver transplantation. Hepatology 32 (2000) 852-858
17. Charlton M., and Wiesner R. Natural history and management of hepatitis C infection after liver transplantation. Semin Liver Dis 24 (2004) 79-88
18. Berenguer M. Systematic review of the treatment of established recurrent hepatitis C with pegylated interferon in combination with ribavirin. J Hepatol 49 (2008) 274-287
19. Berenguer M., Palau A., Aguilera V., Rayon J.M., Juan F.S., and Prieto M. Clinical benefits of antiviral therapy in patients with recurrent hepatitis C following liver transplantation. Am J Transplant 8 (2008) 679-687
20. Carrion J.A., Navasa M., Garcia-Retortillo M., Garcia-Pagan J.C., Crespo G., Bruguera M., et al. Efficacy of antiviral therapy on hepatitis C recurrence after liver transplantation: a randomized controlled study. Gastroenterology 132 (2007) 1746-1756
21. Samuel D., Bizollon T., Feray C., Roche B., Ahmed S.N., Lemonnier C., et al. Interferon-alpha 2b plus ribavirin in patients with chronic hepatitis C after liver transplantation: a randomized study. Gastroenterology 124 (2003) 642-650
22. Samuel D. Antiviral treatment of recurrent hepatitis C after liver transplantation: the need for a multifaceted approach. Hepatology 41 (2005) 436-438
23. Samuel D, Forns X, Berenguer M, Trautwein C, Burroughs A, Rizzetto M, et al. Report of the monothematic EASL conference on liver transplantation for viral hepatitis (Paris, France, January 12-14, 2006). J Hepatol 2006;45:127-43.
24. Narayanan Menon K.V., Poterucha J.J., El-Amin O.M., Burgart L.J., Kremers W.K., Rosen C.B., et al. Treatment of posttransplantation recurrence of hepatitis C with interferon and ribavirin: lessons on tolerability and efficacy. Liver Transpl 8 (2002) 623-629
25. Ramirez S, Massaguer A, Carrion JA, Costa J, Sanchez-Tapias J, Fontdevila C, et al. Hepatitis C virus compartmentalization and infection recurrence after liver transplantation J Hepatol 2007[Abstract];46:S16.
26. Navasa M., and Rodes J. Bacterial infections in cirrhosis. Liver Int 24 (2004) 277-280
27. Cirera I., Bauer T.M., Navasa M., Vila J., Grande L., Taura P., et al. Bacterial translocation of enteric organisms in patients with cirrhosis. J Hepatol 34 (2001) 32-37
28. Navarini A.A., Recher M., Lang K.S., Georgiev P., Meury S., Bergthaler A., et al. Increased susceptibility to bacterial superinfection as a consequence of innate antiviral responses. Proc Natl Acad Sci USA 103 (2006) 15535-15539